SAFETY DATA SHEETS

This SDS packet was issued with item:

071895721

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

070495655 071196757 071196765 071196773 071196781 071895705 071895713 071895739 273000022 71196757 71196765 71196773 71196781

SAFETY DATA SHEET (SDS)

In accordance with Hazard Communication Standard (HCS), 29CFR 1910.1200(g), 2012 revision

SECTION I - PRODUCT/ COMPANY IDENTIFICATION

Product Trade Name: Lollicaine

Common Name: 20% Benzocaine oral anesthetic Part (Item) Number: REF 360088, 360090, 360092, 360094

Manufacturer for: CENTRIX INC

Address: 770 RIVER ROAD, SHELTON, CT 06484

Emergency Telephone Number: Toll-Free (800)235-5862, (203)929-5582

SECTION II: HAZARDS IDENTIFICATION

Classification: Irritant. 1

May be irritating to skin. May cause sensitization by skin contact.

GHS Classification:

Environmental Physical Health Skin Sensitization Category 1(H317) Not hazardous Not hazardous

SECTION III: SECTION III - COMPOSITION

| Hazardous Components | C.A.S.# EC# | IUPAC Name | Substance Classification | WT % |
|-------------------------|---------------------------|---|--|-------|
| Polyethylene Glycol | 25322-68-3 / 500-038-2 | $\begin{array}{c} \text{Poly(oxy-1,2-ethanediyl),} \\ \alpha\text{-hydro-}\omega\text{-hydroxy-} \text{ Ethane-1,2-diol,} \\ \text{ ethoxylated} \end{array}$ | Not classified as hazardous Not classified as dangerous | 30-50 |
| Benzocaine | 94-09-7 / 202-303-5 | ethyl p-aminobenzoate | Sens 1 (H317) Xi, R43 | 20 |

The exact concentration is being withheld as a trade secret.

SECTION IV - FIRST AID MEASURES:

4.1 Description of First Aid Measures:

Routes of Exposure: First Aid Instructions

Flush eyes with large quantities of water for at least 15 minutes, Eye:

holding the eyelids apart. Get medical attention if irritation or

other symptoms persist.

Wash skin thoroughly with soap and water. Get medical attention if Skin:

symptoms develop and persist.

Inhalation: None needed under normal use conditions. If irritation develops,

remove to fresh air. Get medical attention if symptoms persist. If swallowed, call a poison control center. Only induce vomiting if

Ingestion: directed by medical personnel. Never give anything by mouth to an

unconscious person.

4.2 Most Important Symptoms and Effects, Both Acute and Delayed:

Contact with skin, eyes or mucous membranes may cause numbness. Repeated skin contact may cause burning and itching of the skin with dermatitis or rash. =

4.3 Indication of Any Immediate Medical Attention and Special Treatment Needed:

If skin sensitization occurs, discontinue use and get medical attention.

Note to Physicians (Treatment, Testing, and Monitoring): Treatment of overexposure should be directed at the control of symptoms and clinical conditions.

SECTION V - FIRE-FIGHTING MEASURES

Extinguishing media: Water spray or carbon dioxide Special fire-fighting procedures: Use self-contained breathing apparatus

Unusual fire and explosion hazards: none

SECTION VI - ACCIDENTAL RELEASE MEASURES

For large spills, wear gloves and eye protection. Small spills do not require special precautions. Prevent spill from entering sewers and water courses. Report releases as required by local and national authorities. Collect using an inert non-combustible absorbent material and place in appropriate containers for disposal.

SECTION VII - HANDLING AND STORAGE

For professional use only. Avoid contact with the eyes and skin. Wash thoroughly after handling. Use in accordance with package instructions. Store product in original container at cool room temperature (< 25°C) and in a dry, well-ventilated area. Avoid prolonged storage at elevated temperatures as product degradation may occur.

SECTION VIII - EXPOSURE CONTROLS / PERSONAL PROTECTION

Occupational Exposure Limits: Polyethylene Glycol

United States: 10 mg/m3 TWA AIHA WEEL (aerosol) Germany: 1000 mg/m3 (inhalable) DFG MAK

European Union: None Established **SECTION IX - PHYSICAL AND CHEMICAL PROPERTIES**

Physical Data: Boiling point: higher than 250°C

Flash point: Higher than 300°F (Non-combustible liquid)

1.091/25°C Specific gravity: Solubility in water: Disperse 164,000 Centipoise (Brookfield, spindle #6, 5 RPM)

Viscosity: Appearance and odor: Gel with color and specified flavor

Melting point: N/A pH in water: 6.05

Vapor pressure: Nealiaible

SECTION X - STABILITY AND REACTIVITY

Reactivity data: Stability: Stable in ordinary conditions

Incompatibility: Strong oxidizing agents

Hazardous decomposition products: Carbon dioxide and/or monoxide Hazardous polymerization: Will not occurCondition to avoid: None

SECTION XI - TOXICOLOGICAL INFORMATION

Potential Health Effects:

EYES: Direct contact may cause irritation with redness and tearing. Numbness may occur.

SKIN: Direct contact may cause numbness. Prolonged or repeated skin contact may cause contact dermatitis or hypersensitivity to benzocaine with burning, stinging, tenderness and edema.

Ingestion: Swallowing may cause nausea, vomiting and diarrhea. In rare cases, benzocaine has been shown to cause methemoglobemia.

INHALATION: None expected from normal use. Inhalation of mists may cause respiratory irritation.

CHRONIC HEALTH EFFECTS: None expected.

CARCINOGENICITY: None of the components of this product are listed as carcinogens by OSHA, IARC, ACGIH, NTP or EU Directives

MUTAGENICITY: No data available

MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE: Employees with pre-existing skin disorders may be

at increased risk from exposure.

ACUTE TOXICITY DATA: Polyethylene Glycol: Oral mouse LD50 28,900 mg/kg

Benzocaine: LD50 oral rat 3,042 mg/kg

REPRODUCTIVE TOXICITY DATA: No data available SPECIFIC TARGET ORGAN TOXICITY (STOT):

Single Exposure: Benzocaine: When applied topically as recommended, benzocaine has been shown to be

relatively nontoxic, however, sensitization may occur.

Repeated Exposure: Propylene glycol: In 2 week inhalation study, rats were administered whole body

exposure for 6 hr/day for 9 days. No exposure related clinical signs or ophthalmic changes were noted and no mortality was recorded during the study

SECTION XII - ECOLOGICAL INFORMATION

Propylene glycol: Salmo salar (Atlantic salmon) >1000 mg/L

Benzocaine: Readily biodegradable

Benzocaine: Estimated BCF is 5. Potential for bioaccumulation is low.

SECTION XIII - DISPOSAL CONSIDERATIONS

Dispose in accordance with federal, state and local regulations

SECTION XIV - TRANSPORT INFORMATION

| DEGITION AIV | TIANO OTI IN OTIMATION | | | | | | |
|--------------|------------------------|---------------------------------|-------------------------|-----------------------|-------------------------------|--|--|
| | 14.1 UN Num- ber | 14.2 UN Proper Shipping Name | 14.3 Hazard Class(s) | 14.4 Packing Group | 14.5 Environmental Hazards | | |
| DOT | None | Not Regulated | Nones | None | No | | |
| ADR/RID | None | Not Regulated | None | None | No | | |
| IMDG | None | Not Regulated | None | None | No | | |
| IATA/ICAO | None | Not Regulated | None | None | No | | |

SECTION XV - REGULATORY INFORMATION

COMPREHENSIVE ENVIRONMENTAL RESPONSE AND LIABILITY ACT OF 1980 (CERCLA): This product is not subject to CERCLA reporting requirements. Many states have more stringent release reporting requirements. Report spills required under federal, state and local regulations.

TOXIC SUBSTANCES CONTROL ACT (TSCA): This product is a drug and not subject to chemical notification requirements

CLEAN WATER ACT (CWA): Not Listed CLEAN AIR ACT (CAA): Not Listed

SARA Section 311/312 (40 CFR 370) Hazard Categories:

Immediate Hazard: Yes Pressure Hazard: Nο Delayed Hazard: Nο Reactivity Hazard: No

Fire Hazard: No

SECTION XVI - OTHER INFORMATION

Dispose in accordance with federal, state and local regulations

CAUTION

The above information is based on presently available data and to our best knowledge for handling the product under normal conditions. Any use of this product in any way not indicated on this document or using it together with any other process/procedure will be exclusively under the user's responsibility.



CENTRIX INCORPORATED

770 River Road, Shelton, CT 06484 USA (203) 929-5582 (800) 235-5862 FAX (203) 929-6804

www.centrixdental.com

Dental-Contact Vertriebs OHG, Im Spiet 101, DE 26506 Norden

EMERGO AUSTRALIA

Level 20, Tower II, Darling Park, 201 Sussex Street Sydney, NSW 2000, Australia

©2015 Centrix, Inc. Made in the USA Date Revised: 02/2015 012007 REV I